According to MBS’ press release, the BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA). The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range. Read full story
BBI Group Acquires Maine Biotechnology Services
Related Posts
Maine’s life sciences sector growth could outpace other industries
Maine’s $2.3 billion life sciences sector, which employed close to 10,000 people in 2024, will outpace the growth of many other...
IDEXX gets wiggle room to buy back more shares
IDEXX Laboratories Inc. (Nasdaq: IDXX), a Westbrook-based maker of veterinary diagnostics and software, has the green light from its board of...
Maine’s first accredited lab for PFAS testing is expanding to meet demand
NORRIDGEWOCK, Maine — This week, the Biden administration moved to prevent dangerous “forever chemicals” from being released onto the market after a less...